<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Head and Neck Tumors</journal-id><journal-title-group><journal-title xml:lang="en">Head and Neck Tumors</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли головы и шеи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-1468</issn><issn publication-format="electronic">2411-4634</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1130</article-id><article-id pub-id-type="doi">10.17650/2222-1468-2025-15-4-31-40</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ ГОЛОВЫ И ШЕИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Surgical treatment of early-stage oropharyngeal cancer (T1–2N0–2bM0)</article-title><trans-title-group xml:lang="ru"><trans-title>Хирургическое лечение рака ротоглотки ранних стадий (Т1–2N0–2bM0)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9132-3416</contrib-id><name-alternatives><name xml:lang="en"><surname>Kropotov</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Кропотов</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>drkropotov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6287-4836</contrib-id><name-alternatives><name xml:lang="en"><surname>Oganyan</surname><given-names>E. R.</given-names></name><name xml:lang="ru"><surname>Оганян</surname><given-names>Е. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>drkropotov@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6835-5567</contrib-id><name-alternatives><name xml:lang="en"><surname>Alieva</surname><given-names>S. B.</given-names></name><name xml:lang="ru"><surname>Алиева</surname><given-names>С. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>drkropotov@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5889-392X</contrib-id><name-alternatives><name xml:lang="en"><surname>Dobrokhotova</surname><given-names>V. Z.</given-names></name><name xml:lang="ru"><surname>Доброхотова</surname><given-names>В. З.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>drkropotov@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4944-2507</contrib-id><name-alternatives><name xml:lang="en"><surname>Ganina</surname><given-names>K. A.</given-names></name><name xml:lang="ru"><surname>Ганина</surname><given-names>К. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>drkropotov@mail.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-2085-7518</contrib-id><name-alternatives><name xml:lang="en"><surname>Akbieva</surname><given-names>F. M.</given-names></name><name xml:lang="ru"><surname>Акбиева</surname><given-names>Ф. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>drkropotov@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">Медицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Oncological Center No. 1, City Clinical Hospital named after S. S. Yudin, Moscow Healthcare Department</institution></aff><aff><institution xml:lang="ru">Онкологический центр № 1, ГБУЗ г. Москвы «Городская клиническая больница им. С. С. Юдина Департамента здравоохранения г. Москвы»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-03-18" publication-format="electronic"><day>18</day><month>03</month><year>2026</year></pub-date><volume>15</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>31</fpage><lpage>40</lpage><history><date date-type="received" iso-8601-date="2026-02-22"><day>22</day><month>02</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-02-22"><day>22</day><month>02</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Kropotov M.A., Oganyan E.R., Alieva S.B., Dobrokhotova V.Z., Ganina K.A., Akbieva F.M.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Кропотов М.А., Оганян Е.Р., Алиева С.Б., Доброхотова В.З., Ганина К.А., Акбиева Ф.М.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Kropotov M.A., Oganyan E.R., Alieva S.B., Dobrokhotova V.Z., Ganina K.A., Akbieva F.M.</copyright-holder><copyright-holder xml:lang="ru">Кропотов М.А., Оганян Е.Р., Алиева С.Б., Доброхотова В.З., Ганина К.А., Акбиева Ф.М.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ogsh.abvpress.ru/jour/article/view/1130">https://ogsh.abvpress.ru/jour/article/view/1130</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Currently, oropharyngeal cancer is an important problem in oncology due to yearly morbidity growth. Most commonly, human papilloma virus-associated tumors are diagnosed. Tumors of the oropharynx are characterized by aggressive progression and high rate of regional metastases. The main 2 approaches to treatment of this pathology are surgical interventions on the primary lesion in the form of transoral interventions (laser microsurgery, robot-assisted interventions) or, less frequently, open surgeries, with subsequent observation, radiation / chemoradiation therapy per indications or chemoradiation therapy with surgical intervention in cases of residual tumor or locoregional recurrence. Both approaches allow to achieve high overall and recurrence-free survival but differ in complications and functional results.</p> <p><bold>Aim.</bold> To evaluate efficacy of surgical treatment in the form of transoral surgical interventions in patients with early stage Т1–2N0–2bM0 oropharyngeal cancer.</p> <p><bold>Materials and methods.</bold> The study included 120 patients with squamous cell carcinoma of the oropharynx Т1–2N0–2bM0 who underwent surgical treatment in the form of transoral surgical interventions.</p> <p><bold>Results.</bold> Surgical treatment allowed to determine the exact stage of tumor process, form a group with high risk of disease progression, and formulate a plan of postoperative therapy which affected oncological outcomes.</p> <p><bold>Conclusion.</bold> Surgical treatment of oropharyngeal cancer can serve as an independent option or be used in combination with other techniques and allows to achieve good oncological, functional and esthetic results, as well as to plan adjuvant therapy.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Рак ротоглотки на сегодняшний день представляет актуальную проблему современной онкологии, поскольку ежегодно отмечается рост заболеваемости. Чаще всего диагностируют опухоли, ассоциированые с вирусом папилломы человека. Новообразования ротоглотки характеризуются агрессивным течением и высокой частотой регионарного метастазирования. Применяют 2 подхода к лечению этой патологии: хирургические вмешательства на первичном очаге в виде трансоральных (лазерная микрохирургия, робот-ассистированные вмешательства) или, реже, открытые операции с последующим наблюдением, лучевой / химиолучевой терапией по показаниям или химиолучевой терапией с хирургическим вмешательством в случае остаточной опухоли или локорегионарного рецидива. Оба подхода позволяют добиться высоких показателей общей и безрецидивной выживаемости и различаются специфическими осложнениями и функциональными результатами.</p> <p><bold>Цель исследования</bold> – оценить эффективность применения хирургического лечения в виде трансоральных оперативных вмешательств у пациентов с раком ротоглотки ранних стадий – Т1–2N0–2bM0.</p> <p><bold>Материалы и методы.</bold> В исследование включены 120 больных плоскоклеточным раком ротоглотки Т1–2N0–2bM0, которым выполнялось хирургическое лечение в виде трансоральных оперативных вмешательств.</p> <p><bold>Результаты.</bold> Хирургическое лечение позволило на основании данных морфологического анализа материала установить точную стадию опухолевого процесса, сформировать группу риска прогрессирования заболевания и составить план послеоперационной терапии, что повлияло на онкологические результаты.</p> <p><bold>Заключение.</bold> Хирургическое лечение рака ротоглотки может быть как самостоятельной опцией, так и применяться в комбинации с другими методами и позволяет достичь высоких онкологических, функциональных и эстетических результатов, а также спланировать адъювантную терапию.</p></trans-abstract><kwd-group xml:lang="en"><kwd>oropharyngeal cancer</kwd><kwd>transoral laser resection</kwd><kwd>robot-assisted resection</kwd><kwd>chemoradiation treatment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак ротоглотки</kwd><kwd>трансоральная лазерная резекция</kwd><kwd>робот-ассистированная резекция</kwd><kwd>химиолучевое лечение</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">The state of oncological care for the Russian population in 2022. Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2023. 254 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Состояние онкологической помощи населению России в 2022 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2023. Москва, 254 с.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>Lechner M., Liu J., Masterson L., Fenton T.R. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol 2022;19(5):306–27. DOI: 10.1038/s41571-022-00603-7</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Guo T., Eisele D.W., Fakhry C. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer 2016;122(15):2313–23. DOI: 10.1002/cncr.29992</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Singhi A.D., Westra W.H. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010;116(9):2166–73. DOI: 10.1002/cncr.25033</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Cantley R.L, Gabrielli E., Montebelli F. et al. Ancillary studies in determining human papillomavirus status of squamous cell carcinoma of the oropharynx: a review. Patholog Res Int 2011;2011:138469. DOI: 10.4061/2011/138469</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kaczmar J.M., Tan K.S., Heitjan D.F. et al. HPV-related oropharyngeal cancer: Risk factors for treatment failure in patients managed with primary transoral robotic surgery. Head Neck 2016;38(1):59–65. DOI: 10.1002/hed.23850</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Dahlstrom K.R., Garden A.S., William W.N. et al. Proposed staging system for patients with HPV-related oropharyngeal cancer based on nasopharyngeal cancer N categories. J Clin Oncol 2016;34(16):1848–54. DOI: 10.1200/JCO.2015.64.6448</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Gillison M.L. Human papillomavirus and oropharyngeal cancer stage. J Clin Oncol 2016;34(16):1833–5. DOI: 10.1200/JCO.2016.66.6081</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Huang S.H., Perez-Ordonez B., Weinreb I. et al. Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol 2013;49(1):79–85. DOI: 10.1016/j.oraloncology.2012.07.015</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Psyrri A., Rampias T., Vermorken J.B. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2014;25(11):2101–15. DOI: 10.1093/annonc/mdu265</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Mehanna H., Rischin D., Wong S.J. et al. De-escalation after DE-ESCALATE and RTOG 1016: a Head and Neck Cancer InterGroup framework for future de-escalation studies. J Clin Oncol 2020;38(22):2552–7. DOI: 10.1200/JCO.20.00056</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kofler B., Laban S., Busch C.J. et al. New treatment strategies for HPV-positive head and neck cancer. Eur Arch Otorhinolaryngol 2014;271(7):1861–7. DOI: 10.1007/s00405-013-2603-0</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Quon H., Forastiere A.A. Controversies in treatment deintensification of human papillomavirus-associated oropharyngeal carcinomas: should we, how should we, and for whom? J Clin Oncol 2013;31(5):520–2. DOI: 10.1200/JCO.2012.46.7746</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Adelstein D.J., Ridge J.A., Brizel D.M. Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6–7, 2011, Arlington, Virginia. Head Neck 2012;34(12):1681–703. DOI: 10.1002/hed.23136</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Li R.J., Richmon J.D. Transoral endoscopic surgery: new surgical techniques for oropharyngeal cancer. Otolaryngol Clin North Am 2012;45(4):823–44. DOI: 10.1016/j.otc.2012.04.006</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Hinni M.L., Zarka M.A., Hoxworth J.M. Margin mapping in transoral surgery for head and neck cancer. Laryngoscope 2013;123(5):1190–8. DOI: 10.1002/lary.23900</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Cracchiolo J.R., Baxi S.S., Morris L.G. et al. Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base. Cancer 2016;122(10):1523–32. DOI: 10.1002/cncr.29938</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Nichols A.C., Theurer J., Prisman E. et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol 2019;20(10):1349–59. DOI: 10.1016/S1470-2045(19)30410-3</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Cramer J.D., Ferris R.L., Kim S., Duvvuri U. Primary surgery for human papillomavirus-associated oropharyngeal cancer: survival outcomes with or without adjuvant treatment. Oral Oncol 2018;87:170–6. DOI: 10.1016/j.oraloncology.2018.10.039</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Meccariello G., Bianchi G., Calpona S. et al. Trans oral robotic surgery versus definitive chemoradiotherapy for oropharyngeal cancer: 10-year institutional experience. Oral Oncol 2020;110:104889. DOI: 10.1016/j.oraloncology.2020.104889</mixed-citation></ref></ref-list></back></article>
